• Ignacio J Gandino, María José Padilla, Matías Carreras, Valeria Caballero, Sonia López Griskan, Jimena Carlos, Yanina Ametla, Héctor Borodowski, Julieta Ladelfa, Sandra Themines, María Cristina Basta, and José L Presas.
• División Clínica Médica, Hospital General de Agudos Juan A. Fernández, Ciudad Autónoma de Buenos Aires, Argentina. E-mail: ignaciojgandino@gmail.com.
• Medicina (B Aires). 2022 Jan 1; 82 (5): 689-694.

BackgroundCOVID-19 develops severe inflammatory responses that can lead to death. It is essential in a pandemic to have accessible instruments to estimate the prognosis of the disease. The lymphocyte-to-C-reactive protein ratio (LCR) is a predictive biomarker studied in oncology, which could have some advantages in COVID-19 patients in the early stages of the disease. Our objective was to estimate the risk of LCR < 100 and mortality in hospitalized patients with COVID-19.Methodshospitalized patients with COVID-19 seen between March to October 2020 were included. The patients were grouped according to LCR < 100 and LCR > 100. A Cox regression model was performed to estimate the association between LCR < 100 and mortality.Resultswe included 730 patients with COVID-19. The mean age at diagnosis was 49.9 years (SD 16.8) and 401 (55%) were men. Cox regression model showed an association between LCR <100 and mortality (HR 6.2; 95% CI 1.6 to 23.5; p 0.008), adjusting by age. severe pneumonia, intensive care requirements, and comorbidities.ConclusionLPCR <100 in the initial assessment of hospitalized patients with COVID-19 suggests a higher risk of mortality.

13 keywords...

hide…